chartexchange

Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®

GlobeNewswire Inc. | Nov 10, 2026 1:00 AM EST

Lyon (France), November 10, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive five-year antibody persistence data for its single dose chikungunya vaccine IXCHIQ ® . The results demonstrate durable antibody persistence across all age groups evaluated and are consistent with previously reported persistence results 1 , 2 , 3 , 4 . The results are in line with Valneva’s expectations for this vaccine, further supporting IXCHIQ ® 's differentiated profile and its potential to provide long-term protection following a single vaccination, similarly to other live-attenuated vaccines 5 6 .

Read original article